이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Uni-Bio Science Group 관리

관리 기준 확인 4/4

Uni-Bio Science Group's CEO는 Frank Zhao, Apr2019 에 임명되었습니다 의 임기는 5.17 년입니다. 총 연간 보상은 HK$ 900.00K, 67.1% 로 구성됩니다. 67.1% 급여 및 32.9% 보너스(회사 주식 및 옵션 포함). 는 HK$ 483.31K 가치에 해당하는 회사 주식의 0.13% 직접 소유합니다. 483.31K. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 7.4 년입니다.

주요 정보

Frank Zhao

최고 경영자

HK$900.0k

총 보상

CEO 급여 비율	67.1%
CEO 임기	5.3yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	3.9yrs
이사회 평균 재임 기간	7.5yrs

최근 관리 업데이트

Recent updates

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive

May 27

Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?

Apr 24

Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%

Jan 22

Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement

Oct 24

Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)

Apr 30

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Nov 22

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Jan 05

Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth

Mar 01

Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years

Jan 05

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Nov 23

CEO 보상 분석

Frank Zhao 의 보수는 Uni-Bio Science Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	HK$900k	HK$604k	HK$71m
Sep 30 2023	n/a	n/a	HK$67m
Jun 30 2023	n/a	n/a	HK$63m
Mar 31 2023	n/a	n/a	HK$51m
Dec 31 2022	HK$1m	HK$1m	HK$39m
Sep 30 2022	n/a	n/a	HK$16m
Jun 30 2022	n/a	n/a	-HK$7m
Mar 31 2022	n/a	n/a	-HK$13m
Dec 31 2021	HK$2m	HK$907k	-HK$20m
Sep 30 2021	n/a	n/a	-HK$39m
Jun 30 2021	n/a	n/a	-HK$58m
Mar 31 2021	n/a	n/a	-HK$65m
Dec 31 2020	HK$3m	HK$886k	-HK$71m
Sep 30 2020	n/a	n/a	-HK$63m
Jun 30 2020	n/a	n/a	-HK$54m
Mar 31 2020	n/a	n/a	-HK$26m
Dec 31 2019	HK$3m	HK$600k	HK$2m
Sep 30 2019	n/a	n/a	-HK$14m
Jun 30 2019	n/a	n/a	-HK$30m
Mar 31 2019	n/a	n/a	-HK$85m
Dec 31 2018	HK$227k	n/a	-HK$139m
Sep 30 2018	n/a	n/a	-HK$224m
Jun 30 2018	n/a	n/a	-HK$309m
Mar 31 2018	n/a	n/a	-HK$294m
Dec 31 2017	HK$360k	n/a	-HK$279m

보상 대 시장: Frank 의 총 보상 ($USD 115.31K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 232.88K ).

보상과 수익: Frank 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Frank Zhao (59 yo)

5.3yrs

테뉴어

HK$900,000

보상

Mr. Zhi Gang Zhao, also known as Frank, CPA, MSc, has been the Chief Executive Officer and Executive Director of Uni-Bio Science Group Limited since April 8, 2019. He has been the Chief Financial Officer a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kingsley Leung	Executive Chairman of the Board	10.4yrs	HK$1.60m	26.79% HK$ 110.6m
Zhi Gang Zhao	CEO & Executive Director	5.3yrs	HK$900.00k	0.13% HK$ 539.7k
Dawei Chen	Executive Vice Chairman of the Board	7.5yrs	HK$284.00k	2.78% HK$ 11.5m
Kai Du	Financial Controller	2.3yrs	데이터 없음	데이터 없음
Wei Tian	Head of HR & Administration Department	no data	데이터 없음	데이터 없음
Wen Du An	Head of Marketing & Sales	3.9yrs	데이터 없음	데이터 없음
Ya Lei Wen	Head of Manufacture Department	no data	데이터 없음	데이터 없음
HuaNan Zhao	Head of Medicine & Registration Department	no data	데이터 없음	데이터 없음
Jing Li	Head of R&D Department	no data	데이터 없음	데이터 없음
Wing Yan Ho	Company Secretary	2.3yrs	데이터 없음	데이터 없음

3.9yrs

평균 재임 기간

43.5yo

평균 연령

경험이 풍부한 관리: 690 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kingsley Leung	Executive Chairman of the Board	10.4yrs	HK$1.60m	26.79% HK$ 110.6m
Zhi Gang Zhao	CEO & Executive Director	10.3yrs	HK$900.00k	0.13% HK$ 539.7k
Dawei Chen	Executive Vice Chairman of the Board	7.5yrs	HK$284.00k	2.78% HK$ 11.5m
Qingshan Ma	Independent Non-Executive Director	5.3yrs	HK$120.00k	데이터 없음
Kai Ming Chow	Independent Non-Executive Director	8.3yrs	HK$120.00k	데이터 없음
Qimin Ren	Independent Non-Executive Director	6.7yrs	HK$120.00k	데이터 없음
Kwok Wing Yau	Non-Executive Director	5.3yrs	HK$120.00k	데이터 없음

7.5yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: 690 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.

Uni-Bio Science Group 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2024

Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director

Less than half of directors are independent

Less than half of directors are independent

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2022

Uni-Bio Science Group Limited Announces Executive Changes

Recent updates

New minor risk - Share price stability

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive

Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: HK$0.011 (vs HK$0.006 in FY 2022)

Uni-Bio Science Group Limited to Report Q4, 2023 Results on Mar 27, 2024

Uni-Bio Science Group Limited Announces the Acceptance of its Marketing Application for Diquafosol Sodium Eye Drops by the China National Medical Products Administration

Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%

Uni-Bio Science Group Limited Announces Approval of Marketing Application of Bogutai (Teriparatide Injection) by the China National Medical Products Administration

Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement

First half 2023 earnings released: EPS: HK$0.006 (vs HK$0.002 in 1H 2022)

Uni-Bio Science Group Limited to Report First Half, 2023 Results on Aug 28, 2023

Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director

Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)

Full year 2022 earnings released: EPS: HK$0.006 (vs HK$0.003 loss in FY 2021)

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Less than half of directors are independent

First half 2022 earnings released: EPS: HK$0.002 (vs HK$0 in 1H 2021)

Uni-Bio Science Group Limited to Report First Half, 2022 Results on Aug 29, 2022

Uni-Bio Science Group Limited Announces Marketing Application of Bogutai (Teriparatide Injection) Officially Accepted by the China National Medical Products Administration

Less than half of directors are independent

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2022

Uni-Bio Science Group Limited Announces Executive Changes

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021

Uni-Bio Science Group Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth

Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years

Uni-Bio Science Group Limited Announces BOSHUTAI (Acarbose Tablets) Has Been Granted Approval for Marketing in China by the National Medical Products Administration

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Uni-Bio Science Group Limited Updates on the Developmental Potential of the Group's Innovative Biologic Self-Developed Drug Recombinant Exendin-4 Injection

First half earnings released

Uni-Bio Science Group Limited to Report Q1, 2021 Results on Aug 28, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령